The Effect of an EDTA-based Chelation Regimen on Patients with Diabetes Mellitus and Prior Myocardial Infarction in the Trial to Assess Chelation Therapy (TACT)

Circulation: Cardiovascular Quality and Outcomes

Volumn 7, Issue 1, 2014, Pages 15-24

  Escolar, Esteban ^a   Lamas, Gervasio A ^a   Mark, Daniel B ^j   Boineau, Robin ^b   Goertz, Christine ^c   Rosenberg, Yves ^b   Nahin, Richard L ^d   Ouyang, Pamela ^e   Rozema, Theodore ^f   Magaziner, Allan ^g   Nahas, Richard ^h   Lewis, Eldrin F ⁱ   Lindblad, Lauren ^j   Lee, Kerry L ^j  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c PALMER CENTER FOR CHIROPRACTIC RESEARCH   (United States)

^d National Institutes of Health   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f Biogenesis Medical Center   (United States)

^g Magaziner Center for Wellness   (United States)

^h Seekers Centre for Integrative Medicine   (United States)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j DUKE CLINICAL RESEARCH INSTITUTE   (United States)

more..

Author keywords

Diabetes mellitus; Myocardial infarction; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EDETATE DISODIUM; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM CHLORIDE; ORAL ANTIDIABETIC AGENT; VITAMIN B GROUP; WARFARIN;

ANGINA PECTORIS; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHELATION THERAPY; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG INFUSION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART REINFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SENSITIVITY ANALYSIS; TRIAL TO ASSESS CHELATION THERAPY; UNSPECIFIED SIDE EFFECT;

DIABETES MELLITUS; MYOCARDIAL INFARCTION; SECONDARY PREVENTION;

AGE FACTORS; AGED; BLOOD GLUCOSE; CHELATING AGENTS; DIABETES COMPLICATIONS; DOUBLE-BLIND METHOD; EDETIC ACID; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OXIDATION-REDUCTION; RISK FACTORS; TREATMENT OUTCOME;

EID: 84898764346     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.113.000663     Document Type: Article

References (32)

1. Clarke NE, Clarke CN, Mosher RE. The in vivo dissolution of metastatic calcium; an approach to atherosclerosis. Am J Med. Sci. 1955;229:142-149.
2. Clarke CN, Clarke NE, Mosher RE. Treatment of angina pectoris with disodium ethylene diamine tetraacetic acid. Am J Med. Sci. 1956;232:654-666.
3. Grier MT, Meyers DG. So much writing, so little science: a review of 37 years of literature on edetate sodium chelation therapy. Ann Pharmacother. 1993;27:1504-1509.
4. National Institute of Health. EDTA Chelation Therapy for Coronary Artery Disease, RFA-AT-01-004. http://grants.nih.gov/grants/guide/rfafiles/RFA-AT-01- 004.html. Accessed August 8, 2013
5. Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Lindblad L, Lewis EF, Drisko J, Lee KL; Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA. 2013; 309:1241-1250.
6. Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Drisko JA, Lee KL. Design of the Trial to Assess Chelation Therapy (TACT). Am Heart J. 2012;163:7-12.
7. Cranton EM, Liu ZX, Smith IM. Urinary trace and toxic elements and minerals in untimed urine specimens. In: Cranton EM, eds. Textbook on EDTA Chelation Therapy, 2nd Ed. Charlottesville, VA: Hampton Roads Publishing Co; 2001:503-539.
8. Monnier VM. Transition metals redox: reviving an old plot for diabetic vascular disease. J Clin Invest. 2001;107:799-801.
9. American Diabetes Association. Standards of medical care in diabetes- 2013. Diabetes Care. 2013;36:S11-S66.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assn. 1958;53:457-481.
11. Cox DR. Regression models and life-tables (with discussion). J Royal Statist Soc B 1972;34:187-220.
12. Miller RG. Simultaneous Statistical Inference, 2nd ed. New York, NY: Springer-Verlag; 1981.
13. International Diabetes Federation Atlas, 5th ed. 2012. www.idf.org/diabetesatlas/5e/Update2012. Accessed August 8, 2013
14. Carter JS, Pugh JA, Monterrosa A. Non-insulin-dependent diabetes mellitus in minorities in the United States. Ann Intern Med. 1996;125:221-232.
15. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njølstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011; 364:829-841.
16. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, Calvin J, Keltai M, Budaj A. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation. 2000;102:1014-1019.
17. Menke A, Muntner P, Batuman V, Silbergeld EK, Guallar E. Blood lead below 0.48 μmol/L (10 μg/dL) and mortality among US adults. Circulation. 2006; 114:1388-1394.
18. Nawrot TS, Staessen JA. Low-level environmental exposure to lead unmasked as silent killer. Circulation. 2006;114:1347-1349.
19. Navas-Acien A, Selvin E, Sharrett AR, Calderon-Aranda E, Silbergeld E, Guallar E. Lead, cadmium, smoking, and increased risk of peripheral arterial disease. Circulation. 2004;109:3196-3201.
20. Tellez-Plaza M, Guallar E, Howard BV, Umans JG, Francesconi KA, Goessler W, Silbergeld EK, Devereux RB, Navas-Acien A. Cadmium exposure and incident cardiovascular disease. Epidemiology. 2013;24:421-429.
21. Waters RS, Bryden NA, Patterson KY, Veillon C, Anderson RA. EDTA chelation effects on urinary losses of cadmium, calcium, chromium, cobalt, copper, lead, magnesium, and zinc. Biol Trace Elem Res. 2001;83:207-221.
22. Lin JL, Lin-Tan DT, Hsu KH, Yu CC. Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. N Engl J Med. 2003;348:277-286.
23. Chen KH, Lin JL, Lin-Tan DT, Hsu HH, Hsu CW, Hsu KH, Yen TH. Effect of chelation therapy on progressive diabetic nephropathy in patients with type 2 diabetes and high-normal body lead burdens. Am J Kidney Dis. 2012;60:530-538.
24. Manigrasso MB, Juranek J, Ramasamy R, Schmidt AM. Unlocking the biology of RAGE in diabetic microvascular complications.Trends Endocrinol Metab. 2013;pII:S1043-2760.
25. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991;40:405-412.
26. Hodgkinson CP, Laxton RC, Patel K, Ye S. Advanced glycation end-product of low density lipoprotein activates the toll-like 4 receptor pathway implications for diabetic atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28:2275-2281.
27. Goh SY, Cooper ME. The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab. 2008;93:1143-1152.
28. Qian M, Liu M, Eaton JW. Transition metals bind to glycated proteins forming redox active "glycochelates": implications for the pathogenesis of certain diabetic complications. Biochem Biophys Res Commun. 1998;250:385-389.
29. Frizzell N, Baynes JW. Chelation therapy: overlooked in the treatment and prevention of diabetes complications? Future Med Chem. 2013;5:1075-1078.
30. Nagai R, Murray DB, Metz TO, Baynes JW. Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications. Diabetes. 2012;61:549-559.
31. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, Ishikawa N, Nangaku M, Kurokawa K. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol. 2002;13:2478-2487.
32. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, Lee F, Grant SL, Burrell LM, Burrell LA, Jerums G, Osicka TM. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes. 2002;51:3274-3282. Medicine